Skip Navigation

Phase II Multicenter Study of Natalizumab Plus Standard Steroid Treatment for High Risk Acute Graft-Versus-Host Disease

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02133924

Study #:
STUDY00140136

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02133924

View Complete Trial Details & Eligibility at ClinicalTrials.gov